Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform…Updates
Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing...
Biotech Stocks Underperform Market: CELG, EXEL, PBYI, XBI…Updates 5/11…Big Rally on Drug Pricing Speech
Trump Speech on Plan for Lower Drug Prices 5/11 After close. Biotech and healthcare stocks were broadly higher. Key words by HHS Secretary were “complex” and “will take time”; more updates tomorrow. General objectives appear to be to lower list prices and squeeze...
Biotechs Survive 2018 Bottom and Catch a Rally Today…Update 5/9
Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12...
Biotechs Bounce From Support Levels Despite Mixed Earnings Reports…Update 5/3- Testing 2018 Lows
5/3 Testing February bottom and 200 MA of ~$100 on IBB and ~$85 on XBI. Red screen day. 2PM EDT Dow near flat line. Need to look for major gap up. Another potential negative on the horizon: “Bold Action on Drug Pricing” by Sect’y HHS. 5/2 Biotech Stocks Are About To Test 2018...
2018 Biotech Sector Watch on Earnings #2: ABBV, ALXN, BMY…Updates VRTX
Update 4/30… Vertex Pharmaceuticals (VRTX) Beat Consensus by 4% Financial Results: CF Revenues rose 33% Q’18 o Q’17 from $481M to $638M; GAAP net income down 15% ,$210M from $241M. Two Phase 3 triple combination clinical development programs are underway : VX-559 and VX-441...